MIRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MIRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Mira Pharmaceuticals's Accounts Payable for the quarter that ended in Sep. 2024 was $0.69 Mil.
Mira Pharmaceuticals's quarterly Accounts Payable increased from Mar. 2024 ($0.64 Mil) to Jun. 2024 ($0.78 Mil) but then declined from Jun. 2024 ($0.78 Mil) to Sep. 2024 ($0.69 Mil).
Mira Pharmaceuticals's annual Accounts Payable increased from Dec. 2021 ($0.23 Mil) to Dec. 2022 ($0.79 Mil) but then declined from Dec. 2022 ($0.79 Mil) to Dec. 2023 ($0.54 Mil).
The historical data trend for Mira Pharmaceuticals's Accounts Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mira Pharmaceuticals Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
Accounts Payable | 0.23 | 0.79 | 0.54 |
Mira Pharmaceuticals Quarterly Data | ||||||||||||
Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Accounts Payable | Get a 7-Day Free Trial | 0.51 | 0.54 | 0.64 | 0.78 | 0.69 |
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Thank you for viewing the detailed overview of Mira Pharmaceuticals's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Erez Aminov | director, officer: Chief Executive Officer | C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173 |
Brian Patrick Mcnulty | 10 percent owner | C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173 |
Brian Frederick Daly | director | C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173 |
George Cappy | 10 percent owner | C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173 |
David C Vorhoff | director | C/O STAR SCIENTIFIC, INC., 801 LIBERTY WAY, CHESTER VA 23836 |
Chapman Christopher C Jr | director, officer: Executive Chairman | C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814 |
Adam Kaplin | officer: Pres. & Chief Scientific Off. | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Michelle Yanez | officer: CFO, Secretary & Treasurer | 449 S. 12TH STREET UNIT 1705, TAMPA FL 33602 |
Hugh Iii Mccoll | director | 100 RIVER BLUFF DRIVE, SUITE 210, LITTLE ROCK AR 72202 |
Christos Nicholoudis | director | C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173 |
Bradley Kroenig | director | C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173 |
Talhia Tuck | director | C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173 |
Bay Shore Trust | 10 percent owner | C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173 |
From GuruFocus
By ACCESSWIRE • 10-28-2024
By PRNewswire • 08-31-2023
By PRNewswire • 05-21-2024
By ACCESSWIRE • 07-15-2024
By PRNewswire • 05-29-2024
By Nauman Khan • 10-29-2024
By ACCESSWIRE • 08-19-2024
By PRNewswire • 11-29-2023
By PRNewswire • 05-20-2024
By ACCESSWIRE • 07-26-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.